Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trials and tribulations in drug development for nonalcoholic steatohepatitis.

Literature DB >> 25117774

Trials and tribulations in drug development for nonalcoholic steatohepatitis.

Arun J Sanyal¹, Naga Chalasani².

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 25117774 PMCID： PMC4900462 DOI： 10.1016/j.cgh.2014.08.005

Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN： 1542-3565 Impact factor: 11.382

× No keyword cloud information.

13 in total

1. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

Authors: Michael R Charlton; Justin M Burns; Rachel A Pedersen; Kymberly D Watt; Julie K Heimbach; Ross A Dierkhising
Journal: Gastroenterology Date: 2011-07-02 Impact factor: 22.682

2. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors: Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal: N Engl J Med Date: 2010-04-28 Impact factor: 91.245

Review 3. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation.

Authors: Silvia Bijland; Sarah J Mancini; Ian P Salt
Journal: Clin Sci (Lond) Date: 2013-04 Impact factor: 6.124

4. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Authors: Joel E Lavine; Jeffrey B Schwimmer; Mark L Van Natta; Jean P Molleston; Karen F Murray; Philip Rosenthal; Stephanie H Abrams; Ann O Scheimann; Arun J Sanyal; Naga Chalasani; James Tonascia; Aynur Ünalp; Jeanne M Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal: JAMA Date: 2011-04-27 Impact factor: 56.272

5. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.

Authors: Veronique S Chachay; Graeme A Macdonald; Jennifer H Martin; Jonathan P Whitehead; Trisha M O'Moore-Sullivan; Paul Lee; Michael Franklin; Kerenaftali Klein; Paul J Taylor; Maree Ferguson; Jeff S Coombes; Gethin P Thomas; Gary J Cowin; Carl M J Kirkpatrick; Johannes B Prins; Ingrid J Hickman
Journal: Clin Gastroenterol Hepatol Date: 2014-02-25 Impact factor: 11.382

6. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.

Authors: Rifaat Safadi; Fred M Konikoff; Mahmud Mahamid; Shira Zelber-Sagi; Maya Halpern; Tuvia Gilat; Ran Oren
Journal: Clin Gastroenterol Hepatol Date: 2014-05-09 Impact factor: 11.382

Trials and tribulations in drug development for nonalcoholic steatohepatitis.

1. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

2. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Review 3. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation.

4. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

5. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.

6. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.

7. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

8. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.

9. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet.

Review 10. Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver.

1. Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol.

2. Evaluation of Predisposing Metabolic Risk Factors for Portopulmonary Hypertension in Patients with NASH Cirrhosis.